- Sections
- C - Chimie; métallurgie
- C07K - Peptides
- C07K 14/735 - Récepteurs Fc
Détention brevets de la classe C07K 14/735
Brevets de cette classe: 524
Historique des publications depuis 10 ans
|
28
|
36
|
43
|
54
|
73
|
59
|
64
|
74
|
55
|
22
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 3650 |
29 |
| Immunitybio, Inc. | 211 |
29 |
| NantKwest, Inc. | 54 |
17 |
| Cellectis | 397 |
16 |
| Tosoh Corporation | 1127 |
16 |
| FATE Therapeutics, Inc. | 176 |
14 |
| The Trustees of the University of Pennsylvania | 4122 |
13 |
| Xencor, Inc. | 403 |
12 |
| Zymeworks Inc. | 234 |
10 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
9 |
| F. Hoffmann-La Roche AG | 7958 |
8 |
| SuppreMol GmbH | 28 |
8 |
| Novartis AG | 11238 |
7 |
| 1Globe Biomedical Co., Ltd. | 32 |
7 |
| Autolus Limited | 232 |
7 |
| Regents of the University of Minnesota | 2620 |
7 |
| GI Innovation, Inc. | 42 |
7 |
| Hoffmann-La Roche Inc. | 3060 |
6 |
| Chugai Seiyaku Kabushiki Kaisha | 1259 |
6 |
| The Board of Trustees of the Leland Stanford Junior University | 6054 |
5 |
| Autres propriétaires | 291 |